Open-label RCT in 84 patients with HFpEF and atrial functional mitral regurgitation: sacubitril/valsartan improved the 6-month exercise mPAP/CO slope vs standard care (difference -0.93 mm Hg/L/min; P=0.035), with secondary gains in peak VO2 and KCCQ.
RCTn = 84 patients
Dhont et al. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial